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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
Patent Foramen Ovale and Cryptogenic Stroke
To the Editor: The articles by Meier et al.1 and 
Carroll et al.2 and the corresponding editorial by 
Messé and Kent3 (March 21 issue) illustrate a ma-
jor problem in clinical trials. When it is not obvi-
ous which of two therapies is better, sufficient 
numbers of events are essential to reach a con-
clusion. Performing a prospective, randomized 
trial is not enough. In the PC Trial (Clinical Trial 
Comparing Percutaneous Closure of Patent Fora-
men Ovale [PFO] Using the Amplatzer PFO Oc-
cluder with Medical Treatment in Patients with 
Cryptogenic Embolism),1 primary-end-point events 
occurred in only 18 patients in the two groups, 
even though 414 patients and 29 international 
sites participated. Any difference may have been 
due to chance. The investigators in the RESPECT 
(Randomized Evaluation of Recurrent Stroke 
Comparing PFO Closure to Established Current 
Standard of Care Treatment)2 trial enrolled 980 pa-
tients at 69 sites, yet there were only 25 primary-
end-point events. The proper conclusion of these 
studies, even though they were well designed and 
carefully performed, is that too few events were 
observed to draw any conclusion.
When the Early Breast Cancer Trialists’ Col-
laborative Group4 performed the first meta-
analysis of the value of adjuvant tamoxifen — 
one of the most effective medications in our 
pharmacopoeia — for breast cancer, only 6 of 42 
randomized trials had shown significant bene-
fit. Only trials with many patients and many 
events are likely to overcome the play of chance.
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To the Editor: In the primary intention-to-treat 
analysis of the RESPECT trial, recurrent strokes 
occurred in 9 of 499 patients who underwent clo-
sure of a patent foramen ovale and in 16 of 481 
patients in the medical-therapy group (P = 0.08). 
In a secondary as-treated comparison (with pa-
tients classified according to treatment actually 
received), 5 patients in the closure group and 16 in 
the medical-therapy group had a stroke (P = 0.007). 
Although the authors acknowledge that their pri-
mary results did not show a significant benefit of 
closure of a patient foramen ovale over medical 
therapy alone, they conclude that the secondary 
analysis showed “the superiority of closure.”
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However, the secondary analysis appears bi-
ased. Of the 25 patients who were removed from 
the intention-to-treat closure group by the inves-
tigators to form the as-treated group, 4 (16%) had 
a stroke. Because this 16% stroke rate substan-
tially exceeds the 3% background stroke rate 
among patients in the medical-therapy group, 
these 25 patients were not representative of the 
overall study population. Their underlying pre-
disposition to stroke was clearly higher, and re-
moving them from the analysis probably created 
an as-treated group at below-average risk.
In a press release, a representative of the de-
vice company notes the “compelling clinical ben-
efits of closure.”1 The data do not provide support 
for his comments.
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To the Editor: In the RESPECT trial, interven-
tional and medical therapy yielded similar out-
comes in patients with previous cryptogenic 
stroke and a patent foramen ovale. However, a 
subgroup analysis revealed better outcomes with 
percutaneous closure than medical therapy in 
patients with an atrial septal aneurysm or a mod-
erate or severe right-to-left shunt. These results 
compare well with those of previous studies that 
show these anatomic conditions to be associated 
with a higher risk of recurrence of cerebrovascu-
lar events.1,2
The disparate findings between the general 
cohorts and subgroups suggest that patients 
were heterogeneous in terms of clinical risk; 
this resulted in an underpowered study, despite 
the larger number of patients enrolled relative 
to the PC Trial. Indeed, more generally, data 
are lacking from trials that enroll only patients 
with a high-risk patent foramen ovale. None-
theless, risk assessment is only probabilistic in 
this condition. Therefore, while awaiting the 
results of conclusive trials, we recently pub-
lished a position statement on the subject by 
eight national scientific societies.3 This state-
ment proposed that multidisciplinary teams of 
cardiologists, neurologists, and neuroradiolo-
gists (with additional input from hematologists) 
assign treatments on the basis of individual risk 
estimates according to clinical and anatomic 
factors (Fig. 1).
Medical therapy
First cryptogenic event without
anatomical or clinical risk factors
Catheter-based PFO closure as an
alternative to medical therapy
Cryptogenic event in patients with
≥1 risk factor who have not received
medical treatment
Catheter-based PFO closure
Any first or recurrent cryptogenic event
while receiving adequate antiplatelet
therapy, oral anticoagulants, or both
Anatomical Risk Factors
Atrial septal aneurysm
Large PFO (>4 mm)
Basal right-to-left shunt
Eustachian valve >10 mm
Chiari network
Long PFO tunnel
 Clinical Risk Factors
Multiple ischemic lesions on CT or MRI
Recurrent clinical events
History of deep-vein thrombosis, pulmonary embolism, thrombophilia,
or all of these conditions
Embolic event related to Valsalva maneuver
Ischemic event on arousal (the obstructive sleep apnea syndrome)
Event related to travel or immobilization
Simultaneous systemic and pulmonary embolisms
Figure 1. Recommendations for Treatment of Symptomatic or Asymptomatic Cryptogenic Stroke, Transient Ischemic 
Attack with Patent Foramen Ovale, or Both, According to Anatomical and Clinical Risk Factors.
CT denotes computed tomography, MRI magnetic resonance imaging, and PFO patent foramen ovale. Data are 
from Pristipino et al.3
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAET BERN on October 8, 2013. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;1 nejm.org july 4, 201390
Christian Pristipino, M.D.
San Filippo Neri Hospital 
Rome, Italy 
pristipino.c@gmail.com
Francesco Bedogni, M.D.
Istituto Clinico Sant’Ambrogio 
Milan, Italy
Alberto Cremonesi, M.D.
Maria Cecilia Hospital 
Cotignola, Italy
Dr. Pristipino reports being the chairman of the Italian multi-
society position paper on cryptogenic stroke and patent foramen 
ovale, Dr. Cremonesi reports being the president of the Italian 
Society of Invasive Cardiology, and Dr. Bedogni reports being 
the counselor of and in charge of the consensus and position 
documents of the Italian Society of Invasive Cardiology. No 
other potential conflict of interest relevant to this letter was re-
ported.
1. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascu-
lar events associated with patent foramen ovale, atrial septal 
aneurysm or both. N Engl J Med 2001;345:1740-6.
2. Anzola GP, Zavarize P, Morandi E, Rozzini L, Parrinello G. 
Transcranial Doppler and risk of recurrence in patients with 
stroke and patent foramen ovale. Eur J Neurol 2003;10:129-35.
3. Pristipino C, Anzola GP, Ballerini L, et al. Management of 
patients with patent foramen ovale and cryptogenic stroke: a 
collaborative, multidisciplinary, position paper. Catheter Car-
diovasc Interv 2012 August 31 (Epub ahead of print).
DOI: 10.1056/NEJMc1305429
To the Editor: The two recent trials of percuta-
neous closure of patent foramen ovale by Meier et 
al. and Carroll et al. leave unanswered questions. 
Mas et al.1 provide useful guidance for future 
trial designs because they show that the combi-
nation of patent foramen ovale with an atrial sep-
tal aneurysm poses an elevated risk of stroke 
even when the patient receives aspirin. This high-
risk combination clearly warrants consideration 
of either closure or anticoagulation, since anti-
platelet therapy is ineffective. Aspirin alone ap-
pears to be effective for an isolated patent fora-
men ovale.
Many patients and clinicians who are faced 
with the choice of closure or anticoagulation 
would choose closure simply because of the un-
wanted risks and lifestyle modifications associ-
ated with anticoagulation, if the two methods 
were confirmed to be equally safe and effica-
cious. In this case, demonstration of the superi-
ority of closure is unnecessary, since the deci-
sion by the patient and clinician would be served 
just as well by demonstration of noninferiority.
Thus, to show the noninferiority of closure as 
compared with anticoagulation and retain clini-
cal equipoise, a useful trial design might be to 
include patients who have the combination of pat-
ent foramen ovale and an atrial septal aneurysm.
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To the Editor: The results of the RESPECT trial 
and the PC Trial showed no significant differ-
ences in outcomes between closure of the patent 
foramen ovale and medical therapy. The inter-
ventional community must be held responsible 
for the delayed enrollment, which began 10 years 
ago in the RESPECT trial and 13 years ago in the 
PC Trial. Concurrently, Swiss interventionalists, 
including Meier et al., reported a rate of closure 
of a patent foramen ovale that was 10 times as 
high as the total enrollment in the PC Trial; this 
highlights the enormous potential for device 
overuse even before evidence is available.1
Although paradoxical embolism is rarely di-
agnosed during life, it is assumed to be a major 
cause of cryptogenic stroke in young patients. 
Yet, a patent foramen ovale is detected on trans-
esophageal echocardiography in only about half 
these patients. Moreover, rates of stroke recur-
rence are low, and in the first randomized trial 
of closure of a patent foramen ovale, the causes 
of stroke recurrence were not related to a patent 
foramen ovale in 87% of the patients. Unfortu-
nately, the PC Trial and RESPECT investigators 
did not report the cause of stroke recurrence; 
this precludes any clarification of who, if any-
one, is likely to benefit from closure of a patent 
foramen ovale.2
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Drs. Meier and Jüni Reply: Wood and Switch-
enko appropriately point out that both the PC 
Trial and the RESPECT trial were underpowered 
and that definite conclusions cannot be drawn. 
At the outset of the PC Trial, an annual event rate 
of at least 3% was assumed for patients in the 
medical-therapy group. As pointed out by Meyer-
Cestone and Küchler, we estimate that only 5 to 
10% of patients considered for closure of a patent 
foramen ovale were enrolled in the trial, and we 
assume that patients deemed to be at higher risk 
were directly referred for closure of a patent fora-
men ovale rather than being randomly assigned. 
Many investigators did not believe in equipoise of 
closure of a patent foramen ovale and medical 
therapy in these patients. This is likely to have 
resulted in low recruitment rates and consider-
ably lower than expected event rates. Although 
chance is a plausible explanation for the observed 
results, the PC Trial and the RESPECT trial, taken 
together, suggest that a real benefit of closure of 
a patent foramen ovale with the PFO Occluder is 
an appreciably more likely explanation for observed 
results than chance alone.
We concur with Pristipino et al. that the char-
acteristics of a patent foramen ovale affect the 
propensity of a patent foramen ovale to mediate 
paradoxical embolism.1 However, the PC Trial and 
the RESPECT trial did not show a consistent 
outcome in subgroup analyses according to the 
severity of the shunt or the presence of an atrial 
septal aneurysm. Hence, we are uncertain about 
their recommendation that a low-risk patent fo-
ramen ovale should be treated by default with 
medical therapy after a first clinical event. The 
patient might have to be given a choice. The on-
going randomized trials of patent foramen ovale 
(Patent Foramen Ovale Closure or Anticoagu-
lants versus Antiplatelet Therapy to Prevent Stroke 
Recurrence [CLOSE, ClinicalTrials.gov number, 
NCT00562289], Device Closure versus Medical 
Therapy for Cryptogenic Stroke Patients with 
High-Risk Patent Foramen Ovale [DEFENSE-PFO, 
NCT01550588], and Gore Helex Septal Occluder/
Gore Septal Occluder for Patent Foramen Ovale 
[PFO] Closure in Stroke Patients [REDUCE, 
NCT00738894]) are unlikely to have the power 
to specifically address the effect of closure of 
patent foramen ovale as compared with medical 
therapy in subgroups.
The appeal by Pristipino et al. and Newman 
to focus on patients with high-risk patent fora-
men ovales in future trials is well taken. How-
ever, if data from ongoing studies provide sup-
port for closure of the patent foramen ovale with 
an effective device,2 there may be controversy 
about whether random assignment of patients 
with a patent foramen ovale and stroke or sys-
temic embolism to closure or medical therapy 
remains ethical, particularly since medical ther-
apy involves lifelong oral anticoagulation. It is 
appropriate, in our view, to inform patients at 
high risk about the level of invasiveness of closure 
of a patent foramen ovale (i.e., venous puncture 
only, same-day discharge, and no postinterven-
tional restrictions) and the likelihood of superior 
protection against stroke. In turn, the patient 
may opt for closure, which would negatively af-
fect rates of trial recruitment.
Bernhard Meier, M.D. 
Peter Jüni, M.D.
Bern University 
Bern, Switzerland
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Dr. Carroll and Colleagues Reply: Wood and 
Switchenko express concern about the low event 
rates seen in the RESPECT trial. A low risk of 
recurrence may be the true natural history of 
stroke related to patent foramen ovale. Follow-
up from our study is ongoing. We agree that data 
are lacking from a meta-analysis of randomized 
trials, and we are collaborating in a pooled, 
patient-level analysis.
Brett raises the issue of bias in analyses in-
volving different cohorts. We acknowledge that 
bias can occur even with prespecified analyses 
such as those in the RESPECT trial, but we sub-
mit that the totality of evidence must be pre-
sented and discussed.
Pristipino et al. suggest that heterogeneity of 
the treatment effect of closure of patent foramen 
ovale is likely and that risk stratification with 
the use of clinical and anatomic factors may 
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guide clinical practice when definitive evidence 
is lacking. We agree,1 and we analyzed modifiers 
of the treatment effect with the use of a forest 
plot. A trial limited to patients with “high-risk 
patent foramen ovale” is problematic because it is 
not definitively known what features attributable 
to patent foramen ovale pose a high risk of re-
currence.2 We caution that the algorithm pro-
posed in their figure is not based on random-
ized clinical trials but rather predominantly on 
clinical judgment, observational trials, and 
opinion as well as assumptions regarding path-
ophysiologic features.
In our opinion, Newman’s proposed noninfe-
riority trial is not tenable, since anticoagulation 
has not been shown to be superior to antiplatelet 
therapy for a patent foramen ovale, with or with-
out an atrial septal aneurysm.
Meyer-Cestone and Küchler bemoan the slow 
enrollment into the RESPECT trial and suggest 
that practice decisions are ahead of the data, 
especially when closure of the patent foramen 
ovale is the “genie out of the bottle.” Incidental 
patent foramen ovale and recurrent strokes that 
are not related to patent foramen ovale compli-
cate interpretation of trials.2 We agree that the 
cause of stroke recurrence should be ascertained, 
with the caveat that assigning causation is not 
straightforward.3 We recently presented data 
from RESPECT on mechanisms of recurrent 
stroke.4
Finally, in their editorial, Messé and Kent note 
that clinical trials must guard against referral 
bias in adjudicating end points. The RESPECT 
trial used a validated questionnaire at every fol-
low-up visit to identify symptoms of potential 
stroke or transient ischemic attack.5 Any positive 
answer, no matter how trivial, triggered an au-
tomatic review of end points by an adjudication 
committee whose members were unaware of the 
treatment assignments. There were 232 referred 
events in the closure group and 244 referred 
events in the medical-therapy group. The high 
number of referrals (476 candidates with 25 con-
firmed events) and the balance of referrals across 
treatment groups confirm that referral bias was 
unlikely in the RESPECT trial.
John D. Carroll, M.D. 
University of Colorado Denver 
Aurora, CO
Jeffrey L. Saver, M.D. 
University of California, Los Angeles 
Los Angeles, CA
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The Editorialists Reply: We agree with the 
statement by Wood and Switchenko that it would 
be ill-advised to accept as conclusive or definitive 
the results of a small number of studies that each 
had few end points. As we noted in our editorial, 
one or two additional events in either group of 
these studies would lead to dramatically differ-
ent conclusions.
Regarding the comments by Newman: the 
data on the effect of an atrial septal aneurysm 
are mixed at best. Although the cited article by 
Mas et al. showed a significant increase in re-
current stroke in patients with both a patent 
foramen ovale and an atrial septal aneurysm, 
subsequent large, prospective, observational 
cohorts did not confirm this finding.1,2 Even if 
a higher risk of recurrence was established in 
this subgroup, a noninferiority trial comparing 
anticoagulation with closure would not be use-
ful to guide therapy, given that neither inter-
vention has proven efficacy relative to an anti-
platelet medication.
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Circulating Tumor DNA to Monitor Metastatic Breast Cancer
To the Editor: Dawson et al. (March 28 issue)1 
suggest that the detection of circulating tumor 
DNA in 58% of patients with metastatic breast 
cancer can be used as an effective indicator of 
tumor load during treatment with standard sys-
temic therapies. The study does not address the 
clinical utility of circulating tumor DNA. More-
over, the authors claim that circulating tumor 
DNA represents a more effective monitoring tool 
than the enumeration of circulating tumor cells. 
This statement is incorrect, considering that the 
enumeration of circulating tumor cells proved 
the ability to predict prognosis and monitor 
treatment efficacy in all patients with metastatic 
breast cancer, regardless of disease subtype.2 
Furthermore, new detection methods describe 
the molecular heterogeneity and measure dy-
namic phenotypic changes in circulating tumor 
cells during metastasis.3,4 We propose that circu-
lating tumor DNA provides a complementary 
method in the assessment of patients with de-
tectable mutations and should be more appropri-
ately used to select and monitor molecularly tar-
geted therapies. Combined diagnostic methods 
will provide a more effective approach than each 
method alone to the implementation of precision 
medicine and improved clinical outcomes.
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To the Editor: Dawson et al. propose circulat-
ing tumor DNA as a new biomarker for meta-
static breast cancer. In our opinion, the timing of 
the analysis is crucial for the correct interpreta-
tion of such data obtained from samples acquired 
during chemotherapy.
Apoptosis leads to the augmented release of 
cell-free DNA,1 so chemotherapy is expected to 
temporarily increase the levels of circulating 
tumor DNA. Thus, the assumption that such 
increases reflect tumor load may be incorrect, 
depending on the time point chosen.
We suggest a dual role for analysis with cir-
culating tumor DNA. First, the difference be-
tween basal levels before and peak levels after 
the administration of chemotherapy may serve 
as an indicator of tumor responsiveness. Second, 
levels of circulating tumor DNA measured sev-
eral days after the last chemotherapy cycle may 
serve as a surrogate marker for total tumor mass.
Analysis of the kinetics of circulating tumor 
DNA during the use of various chemotherapeutic 
drugs and regimens may pave the way for the 
clinical translation of analysis with circulating 
tumor DNA.
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The Authors Reply: We support the idea that 
combined methods involving circulating tumor 
cells and circulating tumor DNA could be used to 
analyze tumor status and changes. By the crite-
rion of sensitivity for detection of disease bur-
den, our data clearly show an advantage to the 
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